Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany.
Department of Urology, University Hospital Leipzig, Leipzig, Germany.
Eur J Radiol. 2021 Nov;144:109957. doi: 10.1016/j.ejrad.2021.109957. Epub 2021 Sep 17.
Focal therapy with high-intensity focused ultrasound (HIFU) is an emerging option for the treatment of prostate cancer and often followed up by MRI. Image assessment of treatment failure, however, requires proper knowledge about typical procedure-related changes in prostate MRI, which is sparse, in particular for unilateral HIFU treatment and late follow up (beyond 6 months). The goal of this study was therefore to compile the type and frequency of such MRI findings in selected patients without recurrent cancer 12 months after prostate hemiablation.
Data from a prospective multicenter trial on HIFU hemiablation were reviewed retrospectively. Trial patients have had a late follow-up by MRI (at around 12 months) and either MRI/transrectal ultrasound (TRUS) fusion or standard TRUS-guided biopsy. This work deliberately included patients with non-recurrent cancer in the treated prostate lobe in per-protocol biopsy leaving 30 men with initial International Society of Urological Pathology (ISUP) Grade Group of 1 or 2. Six categories of potential HIFU-related MRI features were assessed by an expert committee and then evaluated by two readers in consensus: 1. shrinkage of the treated lobe, 2. residual prostate tissue, 3. fluid-filled cavity, 4. fibrosis, 5. hematoma residuals (in the prostate or seminal vesicles) and 6. contrast enhancement of the ablated area.
Shrinkage of the ablated lobe was seen in 93% of the cases with an average percent volume change of -37% (range: -70% to +108%). In the contralateral lobe, the volume remained practically the same (-2% on average, p = 0.804). In the ablated lobe, the frequency of fibrosis was 97%. Residual prostate tissue was seen in 93% of the cases. The frequency for fluid-filled cavities was 97%, with the wide majority (90%) contiguous with the urethra. Hematoma residuals in the prostate and in seminal vesicles were found in 47% and 10% of the patients, respectively. Contrast enhancement was both rim-like (50%) as well as diffuse (33%) within the ablated area.
In our case series of HIFU hemiablation in the prostate, shrinkage, residual prostate tissue, fluid-filled cavities contiguous with the urethra and fibrosis were very common late MRI findings of the ablated lobe in non-recurrent patients. Rim-like contrast enhancement or diffuse one within the ablated area were less frequent.
高强度聚焦超声(HIFU)的局灶性治疗是治疗前列腺癌的一种新兴选择,通常随后进行 MRI 检查。然而,治疗失败的图像评估需要对前列腺 MRI 中与程序相关的典型变化有适当的了解,而这方面的知识相对较少,特别是对于单侧 HIFU 治疗和晚期随访(6 个月后)。因此,本研究的目的是在前列腺半切除 12 个月后没有复发性癌症的选定患者中,总结这种 MRI 发现的类型和频率。
回顾性审查高强度聚焦超声半切除的前瞻性多中心试验数据。试验患者在晚期通过 MRI(约 12 个月)进行随访,或进行 MRI/经直肠超声(TRUS)融合或标准 TRUS 引导下活检。本研究有意纳入治疗前列腺叶中无复发性癌症的患者,在协议活检中留下 30 名初始国际泌尿病理学会(ISUP)分级组为 1 或 2 的患者。一个专家委员会评估了 6 类潜在的与 HIFU 相关的 MRI 特征,然后由两位读者进行共识评估:1. 治疗叶的收缩,2. 残留的前列腺组织,3. 充满液体的腔,4. 纤维化,5. 前列腺或精囊中的血肿残留,6. 消融区的对比增强。
93%的病例可见消融叶的收缩,平均体积变化为-37%(范围:-70%至+108%)。对侧叶的体积基本保持不变(平均减少 2%,p=0.804)。在消融叶中,纤维化的频率为 97%。93%的病例可见残留的前列腺组织。充满液体的腔的频率为 97%,其中绝大多数(90%)与尿道连续。在前列腺和精囊中的血肿残留分别见于 47%和 10%的患者。在消融区域内可见边缘状(50%)和弥漫状(33%)的对比增强。
在我们的前列腺 HIFU 半切除病例系列中,在非复发性患者中,消融叶的晚期 MRI 发现非常常见的是收缩、残留的前列腺组织、与尿道连续的充满液体的腔和纤维化。消融区内的边缘状或弥漫状对比增强则不太常见。